for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shilpa Medicare Ltd

SHME.NS

Latest Trade

318.65INR

Change

-9.55(-2.91%)

Volume

14,817

Today's Range

315.50

 - 

335.00

52 Week Range

208.10

 - 

435.05

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Latest Developments

India's Shilpa Medicare Sept Quarter Consol Net Profit Rises

Nov 11 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::SEPT QUARTER CONSOL NET PROFIT 507.8 MILLION RUPEES VERSUS 422.7 MILLION RUPEES YEAR AGO.SEPT QUARTER CONSOL REVENUE FROM OPERATIONS 2.90 BILLION RUPEES VERSUS 1.62 BILLION RUPEES YEAR AGO.

Shilpa Medicare Gets USFDA Final Nod For Erlotinib Tablets

Nov 6 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::GETS USFDA FINAL NOD FOR ITS ANDA, ERLOTINIB TABLETS, 25 MG, 100 MG, AND 150 MG.

India's Shilpa Medicare Sets Final Dividend Of 1 Rupee Per Share

Sept 23 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::SAYS SETS FINAL DIVIDEND OF 1 RUPEE PER SHARE.

India's Shilpa Medicare June-Qtr Consol Net Profit Drops

Aug 13 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::JUNE QUARTER CONSOL NET PROFIT 157.4 MILLION RUPEES VERSUS 336.4 MILLION RUPEES YEAR AGO.JUNE QUARTER REVENUE FROM OPERATIONS 1.61 BILLION RUPEES VERSUS 1.98 BILLION RUPEES YEAR AGO.

Shilpa Medicare's Raichur Site Gets U.S. FDA Form 483 With 5 Observations

July 29 (Reuters) - India's Shilpa Medicare Ltd <SHME.NS>::RECEIVED FORM 483 WITH 5 OBSERVATIONS AFTER U.S. FDA AUDIT AT RAICHUR SITE; OBSERVATIONS "MOSTLY PROCEDURAL".

Shilpa Medicare Gets USFDA Final Approval For Its ANDA, Docetaxel Injection

May 17 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::SAYS RECEIVED U.S FOOD AND DRUG ADMINISTRATION FINAL APPROVAL FOR ITS ANDA, DOCETAXEL INJECTION.

Shilpa Medicare Gets U.S. FDA Final Nod For ANDA, Zoledronic Acid Injection

May 16 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::RECEIVED U.S. FOOD AND DRUG ADMINISTRATION FINAL APPROVAL FOR ITS ANDA, ZOLEDRONIC ACID INJECTION, 4 MG/5 ML.

Shilpa Medicare Gets U.S. FDA Tentative Nod For ANDA, Bortezomid For Injection, 3.5Mg/Vial

April 9 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::GETS U.S. FDA TENTATIVE APPROVAL FOR ITS ANDA, BORTEZOMID FOR INJECTION, 3.5MG/VIAL.

Shilpa Medicare Gets USFDA Approval For Its ANDA, Gemcitabine For Injection USP

Feb 25 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::SAYS GOT USFDA APPROVAL FOR ITS ANDA, GEMCITABINE FOR INJECTION USP, 200 MG/VIAL AND 1 G/VIAL.SHILPA MEDICARE-DRUG IS GENERIC EQUIVALENT OF DRUG USED IN TREATMENT OF OVARIAN CANCER, BREAST CANCER, NON-SMALL CELL LUNG CANCER & PANCREATIC CANCER.

India's Shilpa Medicare Dec-Qtr Net PAT Falls

Feb 7 (Reuters) - Shilpa Medicare Ltd <SHME.NS>::DEC QUARTER CONSOL NET PAT 124.7 MILLION RUPEES VERSUS 173 MILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 1.73 BILLION RUPEES VERSUS 1.86 BILLION RUPEES YEAR AGO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up